GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H...

AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported...

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update Proforma cash of approximately $23.0 million includes $16.5 million in cash as of December 31, 2022, plus $6.5 million in gross proceeds received from a registered direct offering priced at a premium...

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer BRISBANE, CALIFORNIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative...

Marina Biotech Appoints Jay D. Schwartz to serve as Senior Vice President, Commercial Operations City of Industry, CA, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of...